Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01008059 · ClinicalTrials.gov registry record · NA
Alfentanil: Simultaneous Testing Pilot
A NA study of Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01008059 is a NA study of Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A that has completed, run by Washington University School of Medicine. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01008059, a NA study of Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A activity.
Conditions Studied
Interventions
- DRUG Alfentanil
Study Locations (1)
Missouri
- Washington University/Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-10 |
| Est. Completion | 2016-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01008059
The ClinicalTrials.gov registry entry for NCT01008059 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A appearing as the primary indexed condition, and to 1 intervention - of which Alfentanil is the first listed.
NCT01008059 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01008059 about?
NCT01008059 is a clinical study titled "Alfentanil: Simultaneous Testing Pilot". To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A activity.
What is the current status of trial NCT01008059?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2009-10. Estimated completion is 2016-09.
What conditions does trial NCT01008059 study?
This clinical trial studies the following conditions: Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A.
What interventions are being tested in trial NCT01008059?
The interventions under investigation include: Alfentanil (DRUG).
Who is sponsoring clinical trial NCT01008059?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01008059 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.